Authors’ reply to: “Projected cost savings of twice-daily Candidozyma auris screening: The need for prospective validation”
American Journal of Infection Control · 2026-12 · 54 (12) · 1377
DOI: 10.1016/j.ajic.2026.09.013 ↗Kurz gefasst
Leserbrief in der Zeitschrift American Journal of Infection Control, 2026-12. Verfasst von Rossana Rosa und 1 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Memorial University of Newfoundland, St. John's, Newfoundland, Canada; Department of Medicine, Dalhousie University, Halifax, No…. Die Arbeit nennt 1 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Faculty of Medicine, Memorial University of Newfoundland, St. John's, Newfoundland, Canada; Department of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada; Department of Medicine, Horizon Health, Fredericton…
- Department of Infection Prevention and Control, Jackson Health System, Miami, FL, USA.
Zitieren
APA
Rosa, R., & Manzanillo, K. (2026). Authors’ reply to: “Projected cost savings of twice-daily Candidozyma auris screening: The need for prospective validation”. American Journal of Infection Control, 54(12), 1377. https://doi.org/10.1016/j.ajic.2026.09.013
Vancouver
Rosa R, Manzanillo K. Authors’ reply to: “Projected cost savings of twice-daily Candidozyma auris screening: The need for prospective validation”. American Journal of Infection Control. 2026;54(12):1377. doi:10.1016/j.ajic.2026.09.013
BibTeX
@article{Rosa2026,
author = {Rosa, Rossana and Manzanillo, Kelley},
title = {Authors’ reply to: “Projected cost savings of twice-daily Candidozyma auris screening: The need for prospective validation”},
journal = {American Journal of Infection Control},
year = {2026},
volume = {54},
number = {12},
pages = {1377},
doi = {10.1016/j.ajic.2026.09.013}
}
EUVIMED